Neil Ahluwalia

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 288 citations · Full text

Pharmacy, Pediatrics, Pharmacology +15

Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells

Eric A. Heller, Emerson Liu, Andrew M. Tager et al. · Circulation · 2006 · 285 citations

Life Sciences, Immunology, Pathology +17

Triple Therapy for Cystic Fibrosis <i>Phe508del</i> –Gating and –Residual Function Genotypes

Peter J. Barry, Marcus Mall, Antonio Álvarez et al. · New England Journal of Medicine · 2021 · 275 citations · Full text

Life Sciences, Genetics, Pharmacotherapy +16

ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis

David Lagares, Parisa Ghassemi-Kakroodi, Caroline Tremblay et al. · Nature Medicine · 2017 · 170 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +11